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A B S T R A C T
Background: Recent studies have demonstrated the eff icacy of the transcatheter valve-in-valve 
implantation for the treatment of bioprosthesis dysfunction in high-risk surgical patients. This study 
presents the initial experience with valve-in-valve implantation.
Methods: Clinical, echocardiographic, and procedural profiles were characterized, and the mid-term 
results of patients with surgical bioprosthesis dysfunction submitted to valve-in-valve implantation in the 
aortic position were reported.
Results: Seven male patients were included, aged 72.6 ± 10.0 years. The STS score was 9,6 ± 10,5%,  and 
the logistic EuroSCORE was 22.7 ± 14.7%. Three patients had combined aortic bioprosthesis failure; 
two had isolated regurgitation; and two had isolated stenosis. The transfemoral access was used in six 
cases, and the transapical access in one case. Implanted devices included Sapien XT (n = 5) and CoreValve 
(n = 2) prostheses. Procedural success was achieved in six (85.7%) cases. After the procedure, the mean 
gradient decreased from 38.2 ± 9.6 mmHg to 20.9 ± 5.9 mmHg, and the valve area increased from 1.2 ± 
0.4 cm2 to 1.5 ± 0.5 cm2. After 1 year, there were no deaths and no other significant adverse outcomes; 
80% of patients were in NYHA functional class I/II. The transvalvular gradients and valve area remained 
unchanged in this period.
Conclusions: The valve-in-valve procedure was effective in most high-risk surgical patients with 
bioprosthesis dysfunction. When performed in well-selected patients, it results in satisfactory clinical and 
hemodynamic outcomes.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Implante transcateter valve-in-valve para disfunção de biopróteses cirúrgicas 
aórticas
R E S U M O
Introdução: Estudos recentes têm demonstrado a eficácia do implante transcateter valve-in-valve para o 
tratamento de disfunção de biopróteses em pacientes de alto risco cirúrgico. Apresentamos nossa experiência 
inicial com o implante valve-in-valve.
Métodos: Caracterizamos o perfil clínico, ecocardiográfico e do procedimento, e reportamos os resultados de 
médio prazo de pacientes com disfunção de bioprótese submetidos a implante valve-in-valve em posição aórtica.
Resultados: Incluímos sete pacientes do sexo masculino, com idade de 72,6 ± 10,0 anos. O escore STS foi 9,6 
± 10,5%, e o EuroSCORE logístico foi 22,7 ± 14,7%. Três pacientes apresentavam dupla disfunção; dois tinham 
insuficiência; e dois exibiam estenose isolada. A via transfemoral foi utilizada em seis casos, e a transapical, em 
um caso. Os dispositivos implantados incluíram as próteses Sapien XT (n = 5) e CoreValve (n = 2). O sucesso do 
procedimento foi obtido em seis (85,7%) casos. Após o procedimento, o gradiente médio reduziu-se de 38,2 ± 9,6 
mmHg para 20,9 ± 5,9 mmHg, e a área valvar elevou-se de 1,2 ± 0,4 cm2  para 1,5 ± 0,5 cm2. Ao final de 1 ano, não 
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Introduction
Patients with surgical bioprosthesis valve dysfunction represent a 
clinical challenge because, although a new surgical replacement is 
considered the standard treatment, the reoperation is associated with 
high morbidity and mortality.1,2 These patients are characterized as 
high surgical risk or inoperable, due to multiple comorbidities, advan-
ced age, clinical frailty, or reduced ventricular ejection fraction.3
Originally developed for the approach of the native valve stenosis, 
transcatheter aortic prosthesis implantation is the standard treat-
ment for symptomatic patients considered inoperable, in addition to 
representing an alternative therapeutic strategy to surgical valve re-
placement in high surgical-risk individuals.4-8 Recent studies demons-
trate the clinical efficacy of transcatheter valve-in-valve (VIV) 
prosthesis implantation for the treatment of aortic surgical biopros-
thesis dysfunction. This is a less invasive treatment option, especially 
because it does not expose the patient to extracorporeal cardiopul-
monary circulation and the inherent risks of reoperation. Although 
the prostheses have not been designed for this purpose, the published 
results have been encouraging.9-14
This study aimed to characterize the initial experience of a multi-
disciplinary cardiovascular team in employing the VIV procedures in 
patients with surgical bioprosthesis dysfunction in the aortic posi-
tion. Clinical and echocardiographic profiles and the aspects related 
to the procedure were described, as well as the clinical results of the 
mid-term follow-up.
Methods
Patient selection and indication for the valve-in-valve procedure
This analysis included patients older than 18 years with sympto-
matic aortic bioprosthesis dysfunction, consecutively submitted to 
VIV procedure at two tertiary cardiology centers between January 
2009 and June 2015. Patients with previous transcatheter aortic val-
ve procedures or active infective endocarditis were excluded from 
the sample. The project was approved by the institutional Ethics 
Committee, and the patients signed an informed consent. Data were 
prospectively recorded in appropriate forms developed for the stu-
dy, stored in spreadsheets, and collected from the database of each 
institution.
Pre-procedure clinical assessment
In general, patient assessment for the VIV procedure was similar 
to that performed in patients candidates for transcatheter aortic val-
ve implantation in native position. The treatment indication was ba-
sed on surgical risk, determined by clinical characteristics or 
technical reasons. For risk estimation, the Society of Thoracic Surge-
ons score (STS, available at http://riskcalc.sts.org/de.aspx) and the 
European System for Cardiac Operative Risk Evaluation score (logis-
tic EuroSCORE, according to http://www.euroscore.org/calcold.
html) were used. Risk factors not included in these scores, such as 
the presence of "porcelain aorta", frailty, hostile thorax caused by 
ocorreram óbitos e nem outros desfechos adversos significativos; 80% dos pacientes encontravam-se em classe 
funcional NYHA I/II. Os gradientes transvalvares e a área valvar permaneceram inalterados nesse período.
Conclusões: O procedimento valve-in-valve foi eficaz na maioria dos pacientes de alto risco cirúrgico com 
disfunção de bioprótese. Quando realizado em pacientes bem selecionados, resulta em desfechos clínicos e 
hemodinâmicos satisfatórios.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
previous chest irradiation, liver diseases, and coagulation disorders, 
were also considered in this decision. All cases were analyzed and 
discussed by a multidisciplinary group (the Heart Team), consisting 
of clinical and interventional cardiologists, cardiovascular surgeons, 
and cardiac imaging specialists.
Specific characteristics of the surgical prosthesis were assessed 
to support the indication of VIV procedure. The type, model, size, 
and position (intra- or supra-annular) of the surgical valve prosthe-
sis were identified. The internal diameter of each bioprosthesis 
was obtained from the manufacturer’s information. Technical as-
pects of the employed surgery, such as the need for reconstruction 
of the aortic root and the presence of venous or arterial grafts, 
were also elucidated.
Complementary pre-procedure examinations
Laboratory tests, electrocardiogram, chest X-rays, transesopha-
geal echocardiography, computed tomography angiography (CT-an-
giography) of the heart and total aorta, and coronary angiography 
were performed.
The main parameter considered for the choice of transcatheter aor-
tic prosthesis to be implanted was the internal diameter of the previous 
surgical bioprosthesis, obtained from the manufacturer or as reported 
by the VIV Aortic application, developed by Bapat and UBQO Ltd. (Lon-
don, United Kingdom).15 Echocardiography was used to assess the me-
chanism and consequences of prosthetic dysfunction, defining the 
integrity and mobility of the leaflets, left ventricular function, and the 
presence of pulmonary hypertension and associated valve diseases. In 
cases of dysfunction due to prosthesis regurgitation, the transesopha-
geal echocardiography excluded the presence of paravalvular reflux. 
The CT-angiography of the aorta was the method used to determine the 
best approach. In case of non-availability of previous surgical data, the 
CT-angiography helped to analyze the surgical prosthesis diameters 
and to choose the most appropriate transcatheter prosthesis for VIV 
procedure. Coronary angiography was used for the assessment of asso-
ciated coronary artery disease and to estimate the risk of coronary oc-
clusion during valve implantation.
Technical aspects of the procedure
Dual antiplatelet therapy (acetylsalicylic acid, 300 mg, and clopi-
dogrel, 300 mg) was initiated with a loading dose 24 hours before 
the procedure. The procedures were preferably performed in the 
hybrid room. The decision regarding use of general anesthesia and 
transesophageal echocardiography was made at the discretion of 
the operators.
The femoral vascular access was the first choice for the implanta-
tion, and a specific hemostatic device was used for arterial repair me-
diated by ProGlide® suture (Abbott Vascular®, Santa Clara, USA). In 
case of the impossibility of using the femoral approach, the transapi-
cal access was used. After establishing the vascular access, a bolus of 
unfractionated heparin was administered (80 to 100 U/kg).
Considering the fact that, in most cases, the surgical bioprosthetic 
annulus is radiopaque, the identification of the best angiographic 
projection for the implant was obtained by fluoroscopy: a coplanar 
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angle was sought and used as a reference for the adequate positio-
ning of the transcatheter prosthesis. Aortography with visualization 
of the coronary ostia was obtained in order to assess the occurrence 
of coronary obstruction during the procedure.
The self-expanding CoreValve system (Medtronic, Minneapolis, 
USA) and the balloon-expandable Edwards Sapien XT system 
(Edwards Lifesciences, Irvine, USA) were used. Both the choice of 
prosthesis and of the need for pre- or post-dilation were made at the 
discretion of the operators.
Follow-up
Clinical, laboratory, and echocardiographic data were collected 30 
days and 6 months after hospital discharge. Dual antiplatelet therapy 
was recommended at maintenance doses (clopidogrel, 75 mg daily for 
6 months and aspirin, 100 mg daily, continuously). In patients with 
indication for oral anticoagulant use, the drug regimen consisted of 
the association of clopidogrel and warfarin, according to the Inter-
national Normalized Ratio (INR) target between 2.0 and 3.0.
Definitions
The outcomes were categorized according to the Valve Acade-
mic Research Consortium (VARC)-2 criteria,16 and the events were 
adjudicated by two experienced cardiologists. The primary outco-
me analyzed was device success, defined as the implantation of a 
single prosthesis in the planned location, with no prosthesis-pa-
tient mismatch, mean aortic transvalvular gradient < 20 mmHg or 
peak velocity < 3 m/s, and absence of aortic regurgitation ≥ mode-
rate, assessed by echocardiography and aortography. The early 
safety outcome (up to 30 days post-procedure) was defined as the 
combination of mortality from all causes; stroke; life-threatening 
bleeding; acute kidney injury stages 2 or 3, according to the Acute 
Kidney Injury Network (AKIN) score;17 major vascular complica-
tions, or valvular dysfunction requiring reintervention. The clini-
cal efficacy criteria (30 days after the procedure) consisted of the 
combined outcome involving mortality from all causes, stroke, 
rehospitalization for heart failure, New York Heart Association 
(NYHA) functional class III or IV, or VIV prosthesis dysfunction 
(stenosis or regurgitation).16
Other complications were also assessed, such as the need for con-
version to conventional surgery, occurrence of coronary obstruction, 
cardiac tamponade, ventricular septal defect, valve malposition, en-
docarditis, valve thrombosis, conduction disorders, and need for de-
finitive pacemaker implantation.16
Statistical analysis
Continuous variables with normal distribution were described 
as mean and standard deviation or median and interquartile range 
for asymmetric variables. Categorical variables were described as 
absolute numbers and percentages. The comparison between con-
tinuous variables was performed by paired Student’s t-test. 
P-values ≤ 0.05 were considered statistically significant. R software 
version 3.1 was utilized (The R Foundation for Statistical Compu-
ting, Vienna, Austria).
Results
Baseline clinical characteristics
All patients were males, mean age of 72.6 ± 10.0 years, and had 
high surgical risk, with STS score of 9.6 ± 10.5% and logistic EuroSCO-
RE of 22.7 ± 14.7% (Table 1). Most patients (71%) were in NYHA class 
III or IV. Four of the seven patients had previously undergone coro-
nary artery bypass surgery. The time between surgical bioprosthesis 
implantation and VIV procedure was 9.5 ± 2.0 years.
Pre-procedure echocardiographic data 
Three patients had combined aortic bioprosthesis failure; two 
had isolated regurgitation; and two patients had isolated steno-
sis. One patient had been previously submitted to mitral valve 
replacement. All surgical prostheses were bovine pericardium 
prosthesis, with SJ Medical Biocor™ (St. Jude Medical Biocor, St. 
Paul, USA) being used in five patients, SJ Medical Epic™ (St. Jude 
Medical Biocor, St. Paul, USA) in one patient, and Braile™ prosthe-
sis (Braile Biomédica, São José do Rio Preto, SP, Brazil) in another, 
with diameters ranging from 21 to 25 mm. The mean internal dia-
meters of the bioprosthesis were 24.0 ± 3.9 mm, obtained with 
CT-angiography. The maximum and mean gradients, according to 
the echocardiography, were 73.7 ± 25.9 mmHg and 38.2 ± 9.6 
mmHg, respectively. The mean areas of the surgical prostheses 
were 1.2 ± 0.4 cm2. Left ventricular ejection fraction ranged from 
39 to 66%, with a mean of 53.3 ± 8.9%. Four patients had signifi-
cant pulmonary hypertension, with mean systolic pulmonary ar-
tery pressure (SPAP) of 58.3 ± 14.0 mmHg.
Technical aspects of the intervention
Most procedures (six patients) were performed under general 
anesthesia and monitored by transesophageal echocardiogra-
phy; in one patient, sedation and local anesthesia were selected 
(Table 2). The transfemoral access was used in six cases; in these 
individuals, hemostasis was achieved without vascular compli-
cations, using a Perclose™ device. Due to the presence of endo-
prosthesis in the descending aorta, the transapical access was 
used in one patient. Pre-dilation was performed in two patients, 
and post-dilation was required in two patients. The procedure 
time was 112.3 ± 57.0 minutes, and the contrast volume was 63.3 
± 45.4 mL.
The maximum left ventricular/aortic gradient decreased from 
73.7 ± 25.9 mmHg to 38.2 ± 9.6 mmHg (p = 0.01) and the mean gra-
dient, from 38.2 ± 9.6 mmHg to 20.9 ± 5.9 mmHg (p = 0.02). There 
was a significant decrease in SPAP, from 58.3 ± 14.0 mmHg to 37.1 ± 
6.0 mmHg (p = 0.01) and increase in valve area from 1.2 cm2 ± 0.4 to 
1.5 ± 0 5 cm2 (p = 0.18) (Fig. 1).
Device success was achieved in six of the seven patients 
(85.7%). The first patient in the series had moderate patient-pros-
thesis mismatch, with the indexed effective orif ice area of 
0.67cm2/m2, moderate aortic regurgitation, moderate paravalvu-
lar regurgitation, and need for a second prosthesis immediately 
after the procedure. During hospitalization, the patient develo-
ped cardiogenic shock, acute kidney injury (AKIN stage 3) requi-
ring hemodialysis, and respiratory failure, and died 48 hours after 
the procedure.
Two patients had left bundle branch block after the procedure, 
without the need for permanent pacemaker implantation. In-hospi-
tal recovery of six patients was uneventful, and all were discharged 
on the seventh day after the procedure.
Clinical follow-up
At the 30-day follow-up, early safety outcome was achieved in 
85.7% of patients.
After a mean follow-up of 585 days (288-776 days), only one pa-
tient had not yet reached one year post-procedure follow-up. Up to 
12 months, there was no need for re-hospitalization, and 80% of pa-
tients were in NYHA functional class I or II (p = 0.03), thus reaching 
the outcome of clinical efficacy. No significant differences were fou-
nd in transvalvular gradients, in valve area, in left ventricular ejec-
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Table 1
Demographic and clinical characteristics.
Cases Patient
1 2 3 4 5 6 7
Age, years 81 54 82 74 69 68 80
Gender Male Male Male Male Male Male Male
BMI, kg/m2 25.9 21.9 21.1 29.1 23.4 30.7 26.6
Logistic EuroSCORE, % 17.1 12.0 44.4 10.2 26.9 32.5 33.9
EuroSCORE II, % 12.8 3.8 11.5 4.0 14.5 7.7 12.2
STS score, % 8.2 1.6 5.4 2.3 5.8 5.2 9.8
NYHA functional class IV III II III III II III
Other symptoms None None None None Syncope None Angina
Associated comorbidities SAH, DLP, and CRF SAH, DLP, 
previously 
repaired aorta, and 
carotid dissection
SAH and previous 
digestive 
hemorrhage
SAH and DLP SAH, aortic 
aneurysm, and 
definitive PM
SAH, DLP, DM, 
smoking, and 
prostate cancer
SAH, DLP, DM, 
COPD, BPH, and 
mitral valve 
change 9 years 
before
Coronary disease Yes Yes No Yes No Yes Yes
Previous cardiovascular 
interventions
No PCI (2 years before) No CABG (12 years 
before); PCI (2 
years before)
No CABG (10 years 
before)
PCI (18 years 
before), CABG  
(8 years before)
Valvular change, years 7.1 11.3 12.3 10.6 7.1 9.6 8.7
Type of prosthesis Biocor™ Braile™ Biocor™ Biocor™ Biocor™ Biocor™ Epic™
Creatinine pre, mg/dL 1.6 1.2 1.4 1.3 2.3 1.7 1.0
Creatinine clearance pre, 
mL.min.1.732
33.9 72.7 30.7 63.1 25.7 134.7 63.1
AVA pre, cm2 0.9 1.9 1.2 0.8 1.1 0.9 1.4
LVEF pre, % 48 49 66 54 39 57 60
Δ Maximum pre, mmHga 53 64 86 89 120 54 50
Δ Mean pre, mmHga 33 35 49 49 79 30 26
Aortic regurgitation pre Important Important Important Absent Mild Important Important
SPAP, mmHg 48 72 78 44 42 61 63
a Values measured by echocardiography. 
BMI: body mass index; EuroSCORE: European System for Cardiac Operative Risk Evaluation; STS score: Society of Thoracic Surgeons; NYHA: New York Heart Association; SAH: systemic arterial hypertension; 
DLP: dyslipidemia; CRF: chronic renal failure; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; BPH: benign prostatic hyperplasia; PCI: percutaneous coronary intervention; CABG: co-
ronary artery bypass grafting; AVA: aortic valve area; LVEF: left ventricular ejection fraction; Δ: gradient; SPAP: systolic pulmonary artery pressure.
Table 2
Characteristicsof the procedure.
Cases Patient
1 2 3 4 5 6 7
Prosthesis Sapien XT Sapien XT Sapien XT Sapien XT CoreValve Sapien XT CoreValve
Prosthesis size, mm 23 23 23 23 26 23 23
Vascular access Right femoral Apical Right femoral Right femoral Left femoral Left femoral Left femoral
TEE during procedure Yes No Yes Yes Yes No Yes
Time of procedure, minutes 120 90 66 180 200 60 70
Contrast volume, mL 50 35 40 55 150 30 75
Post-dilation Yes No No No No No No
AVA post, cm2 1.3 1.5 1.4 1.2 1.1 2.5 1.7
LVEF post, % 43 47 63 60 39 53 65
Δ Maximum post, mmHga 29 40 45 48 29 33 27
Δ Mean post, mmHga 17 26 26 29 16 17 15
Aortic regurgitation, post Minimal Minimal Minimal Minimal Moderate Absent Minimal
Paraprosthetic regurgitation Absent Absent Absent Mild Moderate Absent Absent
SPAP post, mmHg 37 35 37 26 38 45 43
New LBBB post Yes No No No No No No
Creatinine post, mg/dLb 1.6 1.4 1.0 1.1 3.9 1.6 0.7
Creatinine clearance pre, 
mL.min.1.732
32.9 59.7 43.0 71.7 15.2 58.1 89.3
a Values measured by echocardiography; b highest value within 7 days after procedure. 
TEE: transesophageal echocardiography; AVA: aortic valve area; LVEF: left ventricular ejection fraction; Δ: gradient; SPAP: systolic pulmonary artery pressure; LBBB: left bundle branch block.
tion fraction, or in SPAP, when compared to immediate results: the 
mean left ventricular-aortic gradient was 29.0 ± 8.6 mmHg 
(p = 0.17); the prosthetic valve area was 1.5 ± 0.5 cm2 (p = 0.61); 
left ventricular ejection fraction was 56.0 ± 6.5% (p = 0.25); and 
SPAP was 37.4 ± 4.3 mmHg (p = 0.36) (Fig. 2). No signs of structu-
ral dysfunction or hemodynamic deterioration were identified in 
any case.
Discussion
This study described the initial experience of a multidisciplinary 
group with transcatheter VIV implantation for the treatment of sur-
gical bioprosthesis dysfunction in aortic position in high-risk surgi-
cal patients. Data were obtained in a clinical practice setting and 
confirmed their technical feasibility, providing the treated individu-
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Figure 1. Maximum and mean left ventricular-aortic (LV-Ao) gradient, aortic valve area, LV ejection fraction, and systolic pulmonary artery pressure (SPAP) 1 year after valve-in-valve 
procedure.
als with clinical and hemodynamic benefits in the first 30 days, whi-
ch were maintained at the end of 1 year.
Initially described by Wenaweser et al.,18 the VIV implantation 
has been applied to patients worldwide and its clinical outcomes 
have been analyzed in several series9,19-22 and multicenter studies.11,14 
In these registries, the mean age was 78 years, and surgical risk esti-
mates by logistic EuroSCORE and STS score were 31.3% and 11.3%, 
respectively. This clinical profile is similar to that of the present 
cohort, also comprised of patients considered at high surgical risk 
(logistic EuroSCORE > 20% and STS score > 8%).
In the largest previously published registry, the VIVID (Valve 
In Valve International Data) study, with 429 patients, the success 
rate of the procedure was 93.1%. Within 1 month, 7.6% of the pa-
tients had died, and 92.6% of surviving patients had NYHA class I/II. 
The survival rate was 83.2% at 12 months.14 In the present series, 
the success of the procedure has resulted in significant clinical 
improvement, with most patients (80%) in NYHA functional class 
I/II after the first year.
In general, the clinical success of percutaneous transcatheter 
aortic valve implantation (TAVI) is fundamentally related to the ba-
seline characteristics of the treated patients, to the technique em-
ployed, and to the devices used. Accumulated knowledge plays an 
important role to improve its results. In recent years, in particular, 
important concepts have been applied to VIV procedures. In this 
series, the first treated patient developed moderate mismatch and 
paraprosthetic regurgitation, potentially associated with the size 
of the transcatheter prosthesis used and its position. This patient 
had an adverse outcome, with cardiogenic shock after the procedu-
re. At that stage of the learning curve, characteristics currently re-
cognized as fundamental for VIV procedures had not yet been 
assessed or described.
Therefore, important aspects such as model, design, and size of 
the surgical bioprosthesis with dysfunction should be appraised 
when choosing the size of the transcatheter prosthesis to be implan-
ted. The assessment of the true internal diameter of the surgical 
prosthesis is one of the most important factors in this scenario – un-
derstanding as true diameter the diameter of the inner annulus of 
the bioprosthesis, minus the space occupied by leaflets (porcine or 
bovine pericardium) (Fig. 3).
The knowledge of the fluoroscopic aspect of a particular surgical 
prosthesis defines the optimum position for the transcatheter bio-
prosthesis implantation (usually 15% below the suture annulus for the 
Sapien XT and from zero to 4 mm for the Core Valve prosthesis)24 (Fig. 
4). Currently, the smartphone application developed in 2013 by 
Bapat15 allows access to the necessary structural information of se-
veral surgical prostheses, assisting in the most appropriate choice of 
size and positioning of the VIV prosthesis, thus reducing the possibi-
lity of mismatch and aortic regurgitation.
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Figure 2. Pre-procedure New York Heart Association (NYHA) functional class and 1 year 
after valve-in-valve procedure.
Figure 3. (A) Surgical bioprosthesis with porcine leaflets. (B) Measurement of the bio-
prosthesis internal diameter using a caliper. (C) Subtle distortion of the valve caused by 
the caliper, which can lead to incorrect measurements. First measurement: 22.31 mm. 
(D) Second measurement: 25.74 mm, showing the effect caused by the distortion. (E) 
Porcine valves: true internal diameter (ID) is at least 2 mm less than the stent ID. (F) 
Pericardial valves with leaflets sutured inside the stent frame: true ID is at least 1 mm 
less than the stent ID. (G) Pericardial valves with leaflets sutured outside the stent 
frame: true ID is the same as the stent ID.
Adapted from Bapat et al.23
Figure 4. Valve-in-valve procedure using CoreValve (A-C) and Sapien XT (D-F) prostheses. 
(A) The bioprosthesis radiopaque suture annulus is viewed through fluoroscopy and the 
adequate angulation is verified before the procedure and the landing zone. (B) Release of 
the self-expanding CoreValve prosthesis, slowly and gradually, and control by fluoroscopy. 
(C) Final prosthesis position. (D) Positioning of the balloon-expandable Sapien XT pros-
thesis. (E) Release under fluoroscopy and result after the implantation (F).
In this series, the mean transvalvular gradient after the VIV pro-
cedure was 20.9 ± 5.9 mmHg, and 42% of patients had a mean gra-
dient ≥ 20 mmHg. These values are higher than those commonly 
observed after TAVI in native valve stenosis (≤ 10 mmHg). Studies 
show that the occurrence of severe mismatch (< 0.65 cm2/m2) after 
aortic VIV is 32.1%. Higher transvalvular gradients are, therefore, 
somewhat expected in these procedures: the VIV prosthesis is im-
planted in a non-distensible structure (in this case, the surgical 
prosthesis annulus), resulting in a smaller effective flow area.9,25 
Some patients also have mismatch and high mean baseline gra-
dient after surgical valve replacement (especially with bioprosthe-
sis < 23 mm). This fact also contributes to the observation of higher 
gradients after VIV.14,26 In the current series, however, even patients 
with a mean gradient > 20 mmHg after VIV had significant impro-
vement in symptoms. 
Due to the small sample size, there was no statistically significant di-
fference between the mean gradient obtained after VIV with self-expan-
dable vs. balloon-expandable prosthesis. In the series by Dvir et al., both 
the stenosis mode of bioprosthesis failure and the balloon-expandable 
devices (in comparison with self-expandable devices) were associated 
with higher post-procedure transvalvular gradients.14
In this study, no complications such as stroke or the need for per-
manent pacemaker were observed. In fact, evidence shows that the 
VIV procedure does not increase the risk of conduction disorders, of 
need for pacemaker, and of stroke, when compared to the treatment 
of native valve stenosis.27 The paravalvular regurgitation rates are 
substantially lower when compared to TAVI.9
There were no cases of aortic failure, progressive increase in val-
vular gradient after implantation, or evidence of leaflet degenera-
tion on the echocardiographic serial evaluations.
Conclusions
In this initial study, the valve-in-valve procedure was clinically 
effective, resulting in immediate favorable results in patients with 
aortic bioprosthesis dysfunction and high surgical risk. The clinical 
and hemodynamic benefits were maintained in the midterm follow-
-up. Studies with more patients and longer-term follow-up are still 
required to consolidate its indication, especially in individuals with 
lower surgical risk.
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